Incyte Corp (NASDAQ:INCY)

81.91
Delayed Data
As of Aug 23
 -3.65 / -4.27%
Today’s Change
57.00
Today|||52-Week Range
89.30
+28.81%
Year-to-Date
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
Aug 19 / Zacks.com - Paid Partner Content
How Big Is Celgene's Latest Good News?
Aug 18 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close85.56
Today’s open85.56
Day’s range81.58 - 85.82
Volume1,213,363
Average volume (3 months)1,244,238
Market cap$17.9B
Data as of 4:00pm ET, 08/23/2019

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+217.80%
Earnings growth (next 5 years)+41.50%
Revenue growth (last year)+22.50%
P/E ratio57.7
Price/Sales7.29
Price/Book9.20

Competitors

 Today’s
change
Today’s
% change
SGENSeattle Genetics Inc-2.07-2.64%
IONSIonis Pharmaceutical...+0.11+0.16%
MYLMylan NV-0.70-3.68%
ALXNAlexion Pharmaceutic...-8.16-6.61%
Data as of 4:00pm ET, 08/23/2019

Financials

Next reporting dateOctober 30, 2019
EPS forecast (this quarter)$0.40
Annual revenue (last year)$1.9B
Annual profit (last year)$109.5M
Net profit margin5.82%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
Christiana Stamoulis
Corporate headquarters
Wilmington, Delaware

Forecasts